(Q41154949)

English

Randomized comparison of the safety of Flublok(®) versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥ 50 years of age.

scientific article published on 31 October 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 September 2017

Randomized comparison of the safety of Flublok(®) versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥ 50 years of age. (English)

1 reference

Europe PubMed Central

27 September 2017

influenza vaccine

1 reference

based on heuristic

inferred from title

author name string

Ruvim Izikson

1

1 reference

Europe PubMed Central

27 September 2017

David J Leffell

2

1 reference

Europe PubMed Central

27 September 2017

S Allan Bock

3

1 reference

Europe PubMed Central

27 September 2017

Peter A Patriarca

4

1 reference

Europe PubMed Central

27 September 2017

Penny Post

5

1 reference

Europe PubMed Central

27 September 2017

Lisa M Dunkle

6

1 reference

Europe PubMed Central

27 September 2017

Manon M J Cox

7

1 reference

Europe PubMed Central

27 September 2017

language of work or name

0 references

publication date

31 October 2015

1 reference

Europe PubMed Central

27 September 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

27 September 2017

33

1 reference

Europe PubMed Central

27 September 2017

48

1 reference

Europe PubMed Central

27 September 2017

6622-6628

1 reference

Europe PubMed Central

27 September 2017

Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.097

7 January 2021

A fast track influenza virus vaccine produced in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.097

7 January 2021

Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.097

7 January 2021

Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.097

7 January 2021

Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.097

7 January 2021

Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.097

7 January 2021

Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.097

7 January 2021

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.097

7 January 2021

Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.097

7 January 2021

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.097

7 January 2021

Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.097

7 January 2021

Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.097

7 January 2021

Efficacy of high-dose versus standard-dose influenza vaccine in older adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.097

7 January 2021

Allergic reactions after egg-free recombinant influenza vaccine: reports to the US Vaccine Adverse Event Reporting System

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.097

7 January 2021

Identifiers

10.1016/J.VACCINE.2015.10.097

1 reference

Europe PubMed Central

27 September 2017

1 reference

Europe PubMed Central

27 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41154949&oldid=1775313817"